Document is current
Any future updates will be listed below
-
Authors
Passeron, Thierry https://orcid.org/0000-0002-0797-6570
Ta, Richard
Hospital, Véronique
Betts, Keith A. https://orcid.org/0000-0002-3088-7453
Catillon, Maryaline https://orcid.org/0000-0002-1360-8133
Plays, Calvin
Jullien, Denis https://orcid.org/0000-0002-2995-7928
-
Funding
Funding for this research was provided by:
AbbVie
- License Information
-
More Information
Article History
Received: 10 April 2026
Accepted: 31 July 2026
First Online: 20 August 2026
Declarations
Conflict of Interest: Thierry Passeron has received personal fees from AbbVie, ACM Pharma, Almirall, Boehringer Ingelheim, Bristol Myers Squibb, Calypso, Celgene, Galderma, Genzyme/Sanofi, GlaxoSmithKline, Incyte, Janssen, LEO Pharma, Eli Lilly, Novartis, Roivant Sciences Ltd, Sanofi, Sun Pharmaceuticals, and VYNE Therapeutics and is a co-founder of NIKAIA Pharmaceuticals and founder of SUNLUTION. Richard Ta and Véronique Hospital are employees of AbbVie and may hold stocks/stock options. Keith Betts and Calvin Plays are employees of Analysis Group, Inc., which received payment from AbbVie Inc. for participation in this research. Maryaline Catillon is a former employee of Analysis Group, Inc., which received payment from AbbVie Inc. for participation in this research. Denis Jullien is a consultant for and has received personal fees from AbbVie, Almirall, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Janssen-Cilag, Leo, Lilly, MEDAC, Novartis, and UCB.
Ethical Approval: Ethical approval issued by the Comité Éthique et Scientifique pour les Recherches, les Études et les Évaluations dans le domaine de la Santé (CESREES) on June 15, 2023 (TPS No. 12242458).
